Skip to content
CJC-1295 Pharmacy

An independent reading of the CJC-1295 research record — what the trials show, what the compounding-pharmacy literature claims, and where the published evidence ends.

§ N° VI · References

CJC-1295 References and Citations

Every quantitative claim in the dossier maps to a numbered citation here — Phase I trial, foundational receptor pharmacology, regulatory briefings, and the broader GHRH-analog class literature.

Reference table

The CJC-1295 references and citations on this page constitute the full source set for the dossier. Nineteen entries: the foundational Phase I human dose-escalation trial (Teichman 2006), the GHRH-receptor mechanism papers (Jetté 2005, Alba 2006, Frohman 1995, Zhou 2020, the 2025 GHRHR review), the ipamorelin and GH-secretagogue characterization (Raun 1998, Ishida 2020), the tesamorelin class comparator (Falutz 2007, Stanley 2014), the modified GRF (1-29) chemistry reference, the ConjuChem Phase II halt reporting, the FDA Pharmacy Compounding Advisory Committee briefing, the FDA 503A bulks-list action coverage, the WADA Prohibited List 2026, the long-term GH-treatment safety analysis (Johannsson 2022), and the historical sermorelin pharmacology reference (Frohman 1995). DOIs and PubMed identifiers are listed where available; URLs link to the canonical archive.

All citations are organized by section below in canonical order — peer-reviewed primary research, peer-reviewed reviews, regulatory documentation, and historical / class-context references. Citations marked with PMID or DOI are direct links to the public PubMed or publisher archive.

Cited sources

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Teichman SL, et al. CJC-1295 Phase I pharmacokinetics — half-life and IGF-1 elevation duration data. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  3. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  4. Jetté L, et al. CJC-1295 albumin-conjugation pharmacokinetics in rats — peptide detectable in plasma beyond 72 hours, 4-fold GH AUC over unmodified GRF. Endocrinology. 2005;146(7):3052-3058. ↗
  5. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  6. Teichman SL, et al. Safety and tolerability of CJC-1295 in Phase I dose escalation — no serious adverse reactions; injection-site reactions and transient flushing reported. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  7. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling (review). Rev Endocr Metab Disord. 2025. ↗
  8. Zhou F, Zhang H, Cong Z, Zhao LH, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020;11(1):5205. ↗
  9. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. ↗
  10. Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. ↗
  11. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. ↗
  12. Modified GRF (1-29) — chemistry and pharmacology overview (review compendium, citing primary GRF analog literature). ↗
  13. Aidsmap editorial. Lipodystrophy study halted after patient death (news report on ConjuChem Phase II CJC-1295 trial). aidsmap.com. 2006. ↗
  14. U.S. Food and Drug Administration. FDA Briefing Document — Pharmacy Compounding Advisory Committee (PCAC) Meeting on peptide bulk drug substances. 2024. ↗
  15. World Anti-Doping Agency. The Prohibited List — International Standard (Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). WADA Prohibited List 2026. ↗
  16. Johannsson G, Touraine P, Feldt-Rasmussen U, et al. Long-term safety of growth hormone in adults with growth hormone deficiency: overview of 15,809 GH-treated patients. J Clin Endocrinol Metab. 2022. ↗
  17. Lexology editorial. FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list and sets dates for PCAC review. 2024. ↗
  18. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. ↗
  19. Frohman LA, Kineman RD. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res. 1995;50:65-110. ↗